ProMIS Neurosciences Inc. (PMN)
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
ProMIS Neurosciences, Inc.
- PMN310READOUTCash runway at this date: 3mo
Trials need funding. See this company's dilution risk and cash position.
- Nov 17, 2026TXP1PMN310PMN442PMN267
- Phase 1Completed
A Phase 1a Study of PMN310 In Healthy Volunteers
PMN310, Placebo
Healthy Participants
NCT06105528Enrollment40StartNov 2023Primary CompletionJul 2024CompletionJul 2024 - Phase 1Active, not recruiting
PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)
PMN310, Placebo
Alzheimer Disease, Early Onset
NCT06750432Enrollment144StartDec 2024Primary CompletionDec 2026est.READOUTCompletionDec 2026est.
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 1 | Completed | PMN310, Placebo | NCT06105528 |
| Phase 1 | Active, not recruiting | PMN310, Placebo | NCT06750432 |